

03-08-01/ Attorney's Docket No.: 17248-004U81/4804U8

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Aladar A. Szalay et al.

Art Unit : 1636

Serial No.: 10/516,785

Examiner: Daniel M. Sullivan

Filed

: June 27, 2005

Customer No.: 20985

Confirm. No.: 7336

Title

: Light emitting microorganisms and cells for diagnosis and therapy of diseases

associated with wounded or inflamed tissue

Mail Stop: Amendment Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

## **TRANSMITTAL**

Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement (2 pages), Form PTO-1449 (1 page), cited non U.S. patent documents, and a return postcard for filing in connection with the above-captioned application. Because this Supplemental Information Disclosure Statement is filed prior to receipt of a first Office Action on the merits for the above-captioned application, a fee for filing this statement should not be due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 06-1050, as stated below:

 $\boxtimes$ 

The Commissioner is hereby authorized to charge the fee for the extension of time and any other fee that may be due in connection with this and the attached papers or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

> Respectfully submitted,

Stephanie Seidman Reg. No. 33,779

Attorney's Docket No.: 17248-004US1 / 4804US

Address all correspondence to:


Stephanie Seidman Fish & Richardson P.C. 12390 El Camino Real San Diego, California 92130 Telephone: (858) 678-4777 Facsimile: (202) 626-7796

email: seidman@fr.com

CERTIFICATE OF MAILING BY "EXPRESS MAIL" "Express Mail" Mailing Label Number EV 965983271 US Date of Deposit March 6, 2007

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR \$1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie Seidman





## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Aladar A. Szalay et al.

Art Unit : 1636

Serial No.: 10/516,785

Examiner: Daniel M. Sullivan

Filed

: June 27, 2005

Customer No.: 20985

Confirm. No.: 7336

Title

: Light emitting microorganisms and cells for diagnosis and therapy of diseases

associated with wounded or inflamed tissue

Mail Stop: Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN **ACCORDANCE WITH 37 C.F.R. §§ 1.97-1.98**

Because this Supplemental Information Disclosure Statement is filed before the receipt of a First Office Action on the Merits for the above-captioned application, a fee for filing this statement should not be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 06-1050.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all information known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Forms PTO-1449 (1 page) and copies of the cited non U.S. Patent documents are provided herewith in connection with the above-captioned application.

The documents cited on the Forms PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the information, singly or in any combination thereof, is effective as prior art against the subject application. In

> CERTIFICATE OF MAILING BY "EXPRESS MAIL" "Express Mail" Mailing Label Number EV 965983271 US Date of Deposit March 6, 2007

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.00 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA, 22313-1450.

Stephanie Seidman

Applicant: Szalay et al. Szlal No.: 10/516,785 Fifed: June 27, 2005

Attorney's Docket No.: 17248-004US1 / 4804US Supplemental Information Disclosure Statement

Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing documents and they be made of record in the file history of the above-captioned application.

Respectfully submitted,

Stephanie Seidman

Reg. No. 33,779

Attorney's Docket No.: 17248-004US1 / 4804US

Address all correspondence to:

Stephanie Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-4777
Franciscia: (202) 626, 7706

Facsimile: (202) 626-7796 email: seidman@fr.com

MAR 0.6 2007 Substitute Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 17248-004US1/4804US

Application No. 10/516,785

List of Patents and Publications for Applicant's Information Disclosure Statement

Applicant Aladar Szalay et al.

Filing Date
June 27, 2005

Group Art Unit 1636

(37 CFR §1.98(b))

U.S. Patent Documents

C.C. I atom Bodinonto							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
		none					

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner	Desig.	Document	Publication	Country or			Translation	
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
		none						

Other Documents (include Author, Title, Date, and Place of Publication)						
Examiner	Desig.					
Initial	ID	Document				
	AA	Furlan, R., et al., "Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsing-remitting autoimmune encephalomyelitis in Biozzi AB/H mice," Gene Therapy, 8:13-19, (2001).				
	AB	Hogaboam, C.M., et al., "Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease," Journal of Clinical Investigation, 100(11):2766-2776, (1997).				
	AC	Hogervorst, E.J., et al., "Modulation of experimental autoimmunity: treatment of adjuvant arthritis by immunization with a recombinant vaccinia virus," Infection and Immunity, 59(6):2029-2035, (1991).				
	AD	Lopez-Guerrero, J.A., et al., "Modulation of adjuvant arthritis in lewis rats by recombinant vaccinia virus expressing the human 60-kilodalton heat shock protein," Infection and Immunity, 61(10):4225-4231, (1993).				
	AE	Macdonald, T., "Viral vectors expressing immunoregulatory cytokines to treat inflammatory bowel disease," Gut, 42:460-461, (1998).				
	AF	Ruffini, F., et al., "Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice," Gene Therapy, 8:1207-1213, (2001).				
	AG	Wirtz, S., et al., "Efficient gene delivery to the inflamed colon by local administration of recombinant adenoviruses with normal or modified fibre structure," Gut, 44:800-807, (1999).				

Examiner Signature	Date Considered			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.